Kindred Biosciences (KIN) 10-Q2018 Q3 Quarterly report

Filed: 7 Nov 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: administered, allocated, allocation, analyze, assuming, began, big, brand, buying, channel, chronic, clear, collectability, collection, comfortable, consideration, constrained, contractual, convince, credit, customer, damaged, decreased, deliver, delivered, delivery, disease, distinct, dog, dose, dosing, doubtful, engineered, enhanced, entitled, exceeded, expansion, extent, forecasted, frequency, goal, handling, high, impaired, inbound, increasingly, individual, induced, Inflammatix, inflammatory, intent, intention, inventory, ISO, itching, judgment, kidney, labor, landlord, larger, long, modify, moving, national, network, older, opening, optimized, order, ordered, overhead, party, penetration, PK, placement, point, policy, preliminary, prior, prolonged, promised, promising, protein, published, rapidly, reduction, regional, regular, reinspection, relevant, resell, response, return, returned, reversal, score, single, size, skin, solution, statutory, strong, substance, suggest, sustained, therapeutic, therapy, Trademark, ultimately, uncover, workforce, write

Removed: accrual, collaboration, initiated, metabolic, post, prepare, realization, recoverability, site, syndrome, Web

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated KIN transcripts

KIN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Kindred Biosciences, Inc. (the “Company”) hereby certifies that, to his or her knowledge:

(i) The quarterly report on Form 10-Q for the period ended September 30, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: November 7, 2018	By: /s/ Richard Chin	By: /s/ Wendy Wee
	Name: Richard Chin, MD	Name: Wendy Wee
	Title: Chief Executive Officer	Title: Chief Financial Officer
	(Principal Executive Officer)	(Principal Financial and Accounting Officer)